Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced voting results from its annual and special meeting of shareholders held Sept. 22, 2026, with 46,452,598 common shares represented, or 63.58% of outstanding shares as of the record date. Shareholders appointed Zeifmans LLP as auditor, approved setting the board at eight directors, and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So as directors.
Shareholders also approved changing the company’s legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1. The legal name change follows adoption of the Helus Pharma business name on Jan. 5 and reflects the company’s anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. This shift is significant for investors and the mental health sector because it signals Helus Pharma’s progression toward commercialization of its novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.
Helus Pharma, founded in 2019, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom and Ireland.
The annual meeting results and name change carry implications for the broader biopharmaceutical industry, as Helus Pharma’s transition to a commercial-ready entity could accelerate the availability of new treatment options for depression and anxiety. With class-leading data, the company aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. For more information on Helus Pharma, visit www.helus.com.
The announcement was disseminated through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NNW is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The full press release is available at https://nnw.fm/H4DVg.
